Triple-Drug cocktail aims to boost remission in CLL
NCT ID NCT04624633
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study is testing a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if this triple therapy can improve complete remission rates. The study enrolled 29 participants with either relapsed/refractory or previously untreated CLL.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Acalabrutinib, umbralisib, and ublituximab (three drugs combined)
What this could lead to
If successful, this combination could offer a more effective treatment option for CLL patients, potentially leading to higher remission rates.
What could go wrong
This is a small, early-phase (Phase 2) study with only 29 participants. The combination may not prove more effective than existing treatments and could have side effects from the multiple drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States